# GPT-5.2 Review

**Role:** External referee review
**Model:** openai/gpt-5.2
**Paper:** paper.pdf
**Timestamp:** 2026-03-03T14:00:50.468849
**Route:** OpenRouter + LaTeX
**Review mode:** Tri-model (3 independent reviewers)
**Tokens:** 14468 in / 3786 out
**Response SHA256:** 96e3563980995ea5

---

## Summary

The paper asks an important policy question—whether Extreme Risk Protection Order (ERPO) laws reduce violent crime—and correctly recognizes that staggered adoption makes naive TWFE problematic. The move to Callaway–Sant’Anna (CS) DiD is appropriate and the paper is generally careful about describing limitations. However, as written, the design and inference do not yet meet “top general-interest” standards for a causal claim, mainly because (i) the identifying variation is thin and plausibly confounded by contemporaneous shocks/policies around 2016–2020, (ii) the paper does not show the *actual* design-based diagnostics that are now expected for staggered DiD (full group-time/event-time tables, support/overlap, cohort-specific pretrends, influence of weighting), and (iii) several reported inferential exercises (parallel-trends test, randomization inference, wild bootstrap on TWFE) are either not well-justified or not aligned with the estimand.

Given these issues, I view the paper as promising but not yet publication-ready.

---

# 1. Identification and empirical design (critical)

### 1.1 Core identifying assumption and control group choice
- The causal claim relies on a parallel trends assumption across adopting and never-adopting states (Section “Identification”). This is standard, but the paper’s setting raises unusually strong threats:
  - The dominant adoption mass is 2018–2020 (Institutional Background), coinciding with major nationwide shocks (opioids, COVID-era disruptions, policing changes, protests) that differentially hit states. Your own “Pre-COVID” robustness substantially attenuates the estimate (Table 8: −0.054 vs −0.251), indicating the estimate is sensitive to that era and potentially confounded.
  - ERPO adoption is politically and institutionally bundled with other gun policies (you acknowledge this under “Concurrent policies”). Treating the ATT as an “ERPO-inclusive bundle” is honest, but then the paper’s title and repeated framing (“Do Red Flag Laws Reduce Violent Crime?”) overstates the specificity of what is identified. This is a first-order identification issue, not just a limitation paragraph.

**Concrete fix**: either (a) explicitly redefine the estimand throughout as the effect of an ERPO-policy package and document co-adopted policies; or (b) attempt to isolate ERPO effects with controls for other firearm laws (even if imperfect) and show how the ERPO coefficient changes.

### 1.2 Treatment timing coherence and coding
- Treatment is coded as “in effect for the majority of the calendar year” (Data; Treatment Coding). With annual data, this is reasonable, but it creates non-classical timing error because effective dates vary within year; this matters especially for the 2018 wave (many effective mid/late 2018). That timing error biases effects toward zero and muddies event-time interpretation.
- Connecticut is “always treated” and dropped by CS-DiD; that is fine. But the narrative still uses CT in places as an early adopter shaping TWFE bias (TWFE Comparison). Since CT is not part of CS estimates, you should be careful: TWFE bias discussion that relies on CT dynamics should be documented with decomposition outputs in an appendix, including CT’s role in weights.

**Concrete fix**: provide a table of effective dates (month/day), show how many state-years are “partially treated,” and re-estimate with (i) dropping adoption year (treat from t+1), and/or (ii) coding treatment by fraction of year treated (dose), or at least show robustness.

### 1.3 Staggered DiD implementation details are insufficiently transparent
Top journals now expect the following for staggered adoption:
- A clear statement of the target parameter (which ATT weighting scheme; whether it is exposure-weighted, cohort-size weighted, etc.). You state “weighted average across all group-time cells,” but not the exact weights used by `aggte()` in your implementation.
- Group-time ATTs: You show event study and cohort-specific figure, but not the underlying `ATT(g,t)` table or summary of which cohorts contribute at each event time.

**Concrete fix**: add an appendix table summarizing cohorts, available pre/post periods by cohort, and the weights in the aggregated ATT. Also report the number of treated observations contributing to each event-time coefficient (common support).

### 1.4 Threats not adequately addressed
- **Differential shocks around 2020**: The large difference between full sample and pre-COVID makes this a major concern. Simply presenting both is not enough; you need a design-based strategy to argue why post-2020 is not contaminating identification (or else restrict the main estimand to pre-2020).
- **Policy endogeneity / anticipation**: ERPO adoption often follows salient events (mass shootings). An event study with annual data may not detect short-run anticipation if treatment and shock happen in same year. The Wald pretest p=0.074 (Inference subsection) is already borderline.

**Concrete fix**: (i) present cohort-specific pretrend diagnostics (not just pooled); (ii) run “placebo adoption years” within treated states (shift adoption earlier by 1–3 years) to test whether effects appear when no law existed; (iii) consider excluding the adoption year (as above) to mitigate immediate shock/anticipation conflation.

---

# 2. Inference and statistical validity (critical)

### 2.1 Standard errors and small number of clusters
- You cluster by state, but effective treated clusters are only 18 (and only 2 for LE-only heterogeneity). Asymptotic cluster-robust SEs can be unreliable with few clusters; CS-DiD inference is especially sensitive to bootstrap choices.
- You mention a bootstrap (1,000 iterations) but it is unclear whether this is the default multiplier/bootstrap recommended for CS, whether it is clustered at the state level, and whether it is stratified by treatment cohort.

**Concrete fix**: clearly specify the inference procedure used for CS-DiD (multiplier bootstrap vs block bootstrap), and report (i) 95% CIs, not only SEs; (ii) sensitivity to bootstrap type/seed/iterations; and (iii) consider reporting wild cluster bootstrap p-values/CIs for the *main CS estimand*, not only TWFE.

### 2.2 Parallel trends testing is not “design-valid” as currently used
- The paper reports a Wald test on pre-treatment event-study coefficients (p=0.074 for murder). In staggered DiD, such tests can be misleading because pre-period coefficients at different event times are estimated from different cohorts and different comparisons, and because power varies sharply across leads. Also, “fail to reject” is not evidence of parallel trends.
  
**Concrete fix**: adopt current best practice:
- show event-study leads with cohort composition and standard errors;
- report a *slope-based* pretrend test (e.g., regress estimated leads on event time) and/or placebo leads that are common across cohorts;
- add sensitivity analysis (e.g., Rambachan–Roth / HonestDiD). You say it “could not be computed due to insufficient pre/post periods.” That itself is important: it implies the design may not support credible robustness to violations of parallel trends. You should either (a) restructure event-time window/cohort inclusion to make HonestDiD feasible for main cohorts, or (b) provide alternative sensitivity (e.g., bounded trend deviations).

### 2.3 Randomization inference is not justified as implemented
- You appropriately caveat that unrestricted permutations assume exchangeability (Randomization Inference subsection). But then the reported RI p-value is not informative for causal inference in this observational setting.
  
**Concrete fix**: either drop RI from the main paper, or implement a *structured* permutation consistent with plausible assignment (e.g., permute within regions, within political-party control strata, or adopt Conley–Taber-style placebo distribution using untreated states only). At minimum, do not present RI as corroborating asymptotic inference.

### 2.4 Coherence of N and treated/control counts
- Table 4 states: “18 effectively treated, 31 never-treated controls, 1 always-treated (CT).” That sums to 50, consistent. But some robustness specs change N (drop 2021, pre-COVID). You should report treated/control counts and number of post-treatment treated observations for each robustness spec; otherwise readers cannot assess power.

**Concrete fix**: for each key spec, report: number of treated states contributing; average post-treatment years; and effective sample size in post periods.

---

# 3. Robustness and alternative explanations

### 3.1 The robustness set is not yet targeted to the main threats
Your robustness checks are helpful but miss several high-value diagnostics:

1. **Alternative outcome definitions**  
   - Homicide is clean, but ERPO should most directly affect *firearm* homicides/assaults. Using total murder may dilute the signal.
   - UCR does not always provide firearm-specific homicide reliably at state-year level, but Supplementary Homicide Reports (SHR) or CDC WONDER can.

   **Fix**: add firearm homicide (CDC WONDER underlying cause; or SHR if feasible), and possibly non-firearm homicide as a placebo-substitution test (ERPO should affect firearm more).

2. **Spillovers and SUTVA concerns**  
   - Firearm acquisition and movement across state borders could create spillovers (e.g., ERPO in one state affects neighboring states’ crime via displacement, or cross-border gun sourcing).
   
   **Fix**: include border-state spillover checks (drop neighbors; include region-year shocks; or use spatial lags).

3. **Differential adoption trends / selection on trends**  
   - The biggest concern is that adopters differ in *trend* near adoption. Pre-2016 summary statistics are not enough.

   **Fix**: incorporate state-specific linear trends as a sensitivity (recognizing downsides), and/or use synthetic control style checks for the 2018 mega-cohort.

4. **Concurrent gun laws**
   - This is a central alternative explanation. Without addressing it, the paper cannot claim ERPO effects.

   **Fix**: add controls for major gun policy indices (e.g., RAND State Firearm Law Database; Siegel et al. gun law database) and show robustness.

### 3.2 Mechanisms vs reduced form
- The paper occasionally interprets results in mechanism terms (family petition informational advantage) but your heterogeneity design cannot separate petitioner type from timing/exposure and other state characteristics (you acknowledge confounding).
  
**Fix**: treat the petitioner-type split as descriptive; if kept, implement a triple-difference or interaction design with pre-specified covariates and explicit caveats about identifiability. Alternatively, drop it from main text.

### 3.3 External validity and magnitude interpretation
- The discussion translates a −5% estimate into “~1,050 fewer homicides/year” (Discussion). Given that the estimate is statistically indistinguishable from zero and sensitive to time period, this is too policy-forward.
  
**Fix**: present that calculation as an “upper-bound if the point estimate were true” and pair it with CI-based ranges (including zero and positive effects if applicable).

---

# 4. Contribution and literature positioning

### 4.1 Novelty claim is overstated
- “First multi-state causal analysis … using modern heterogeneity-robust methods” may be true, but the paper should be careful: there is already national work on ERPO and suicide (you cite DeAngelis 2023). For violence/homicide, you should verify whether any recent working papers have applied CS-DiD / Sun-Abraham / Borusyak-Jaravel-Spiess to ERPO or closely related gun policies.

**Fix**: systematically review multi-state ERPO and gun policy DiD studies and clearly distinguish (i) outcome (violent crime vs suicide), (ii) method (heterogeneity-robust), (iii) data (UCR vs CDC).

### 4.2 Missing/needed citations (suggested)
To strengthen both policy and methods positioning, consider adding:
- **Gun law databases / concurrent policy controls**: RAND State Firearm Law Database (and associated documentation papers); Siegel et al. state gun law database.
- **Modern DiD guidance**: Sun and Abraham (2021); Borusyak, Jaravel, and Spiess (2021); Callaway and Sant’Anna (2021) already cited; Roth et al. on event-study pitfalls (you cite Roth 2023 pretest).
- **Small-cluster inference** beyond Cameron et al. (2008): e.g., MacKinnon and Webb wild cluster bootstrap refinements (depending on what you implement).

(Exact bib entries depend on your reference system; the key is to cite the canonical sources for gun-law covariates and alternative staggered DiD estimators.)

---

# 5. Results interpretation and claim calibration

### 5.1 The paper’s bottom line should be more conservative
- You repeatedly suggest “likely modest reductions” and lean toward “underpowered” interpretation. But your own RI diagnostic shows the estimate is common under arbitrary assignment, and the pre-COVID estimate is near zero. The sign stability is not strong evidence when treatment is correlated with time and national shocks.
  
**Fix**: reframe the central result as: “With state-year UCR data and staggered adoption, we cannot rule out economically meaningful reductions, but estimates are imprecise and sensitive to the post-2020 period; credible identification of ERPO-specific effects is challenging without richer outcomes and policy controls.”

### 5.2 TWFE “overestimation” claim is too definitive
- You argue TWFE “overestimates by 3.6×” and attribute this to forbidden comparisons. This may be correct, but you need to show the decomposition outputs and emphasize that TWFE and CS target different weighted averages; “overestimation” is a strong word unless you establish that CS is closer to the causal estimand of interest and that assumptions hold.
  
**Fix**: present TWFE vs CS as “material divergence consistent with heterogeneity bias” and show decomposition in appendix; consider also reporting Sun-Abraham or BJS as additional benchmarks.

---

# 6. Actionable revision requests (prioritized)

## 1) Must-fix issues before acceptance
1. **Address ERPO-specific identification vs bundled gun-policy adoption**
   - *Why it matters*: Without accounting for concurrent gun laws, the paper cannot attribute effects to ERPOs, undermining the title and causal claim.
   - *Fix*: Add controls for other gun laws using a standard database; report how the ATT changes. If not feasible, reframe estimand explicitly as a bundle and adjust title/claims accordingly.

2. **Strengthen staggered DiD transparency and diagnostics**
   - *Why*: Readers must see which cohorts/event-times identify which coefficients and whether overlap/support problems exist.
   - *Fix*: Provide cohort-by-year availability, weights used in aggregation, and a table of `ATT(g,t)` summaries; report cohort-specific pretrend diagnostics.

3. **Upgrade inference for few clusters for the main CS estimates**
   - *Why*: Valid inference is required; 18 treated clusters is borderline.
   - *Fix*: Report wild cluster bootstrap (or appropriate CS multiplier bootstrap) CIs for the main ATT and key event-study points; document procedure fully.

4. **Treatment timing sensitivity (adoption-year handling)**
   - *Why*: Annual coding with “majority of year” plus shock-driven adoption creates timing error and anticipation confounding.
   - *Fix*: Re-estimate with adoption year excluded (treat starting t+1), and/or alternative coding; present as a main robustness check.

## 2) High-value improvements
5. **Use firearm-specific outcomes and substitution placebos**
   - *Why*: Mechanism predicts firearm violence reductions; total murder is diluted.
   - *Fix*: Add firearm homicide (CDC WONDER / SHR) and non-firearm homicide placebo.

6. **Deal explicitly with 2020–2023 structural break**
   - *Why*: Pre-COVID vs full sample divergence suggests instability.
   - *Fix*: Make 2000–2019 a co-primary analysis, or include flexible time controls (region-by-year) and show stability.

7. **Benchmark against additional modern staggered estimators**
   - *Why*: Strengthens credibility that results are not estimator-specific.
   - *Fix*: Add Sun–Abraham and/or BJS as robustness.

## 3) Optional polish
8. **Recalibrate policy extrapolations**
   - *Why*: CI includes zero; national homicide extrapolation is too strong.
   - *Fix*: Present CI-based implied lives saved and label as hypothetical.

9. **Heterogeneity by petitioner type**
   - *Why*: N=2 in LE-only makes it anecdotal.
   - *Fix*: Move to appendix or drop; if kept, present as descriptive and confounded.

---

# 7. Overall assessment

### Key strengths
- Important policy question with clear relevance.
- Correctly avoids naive TWFE as the main estimator and highlights heterogeneity concerns.
- Honest discussion of limitations; several useful robustness checks (drop 2021, not-yet-treated, leave-one-out).

### Critical weaknesses
- Identification is not yet convincing for an ERPO-specific causal claim due to concurrent policies and major contemporaneous shocks (especially 2020+), plus coarse annual timing.
- Inference and diagnostics are not yet at the standard expected for staggered DiD with few treated clusters; pretrend testing and RI are not persuasive as implemented.
- Over-interpretation risk: policy extrapolations and “TWFE overestimation” language are too strong given design fragility.

### Publishability after revision
With major additions—especially policy-bundle controls or reframing, improved inference, and more design transparency—the paper could become a solid AEJ:EP-style contribution. As-is, it falls short of top general-interest readiness.

DECISION: MAJOR REVISION